SEC Filings
ARK Reports 11.43% Of Beam Therapeutics — Its Stake Retains Passive Status
ARK Innovation ETF was the client identified as holding an interest above 5% in the reported shares.
Beam Therapeutics (BEAM) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
ARK Innovation ETF was the client identified as holding an interest above 5% in the reported shares.
SEC Filings
The gene-editing company says cash plus a $200 million credit draw lasts into mid-2029, with cash at $1.0 billion.
Earnings
Beam's quarterly collaboration revenue fell to $0.3 million as Biogen moved to end its rights, effective December 2026.